InhibitCon Agenda Release - 👩‍⚕️👨‍⚕️See Who's Coming

InhibitCon Agenda Released! Check out all the speakers and professionals we have coming!

We have also updated who can attend, check the details section below!

Click to View the Weekend Agenda

Registration is OPEN!
Details for signing up are below
Dates: August 2nd - August 4th 2024

The Details:

Scheduled August 2-4, 2024
Located at Houston Airport Marriott, Texas
Participants age 12+ managing an inhibitor with one parent/guardian are invited to attend
One Parent/Guardian may attend if child is under the age of 12
Adults 18+ managing an inhibitor are invited to attend, caregivers and parents of an adult may also attend if they need travel assistance and/or are still on their parents insurance
More information available by clicking the button below:

Learn More About InhibitCon Here

InhibitCon is a new CHES Foundation program with three distinct tracks designed for the inhibitor community: Caregiver, Adult Men and Tweens/Teens. The adult track will keep CHES’ long standing Momentum inhibitor program intact.

This weekend program is packed full of education and support. We to continue to work alongside GutMonkey and their amazing programming skillset!

How much does it cost to attend?

There are little to no costs associated with attending once the trip is completed. Because of numerous, last-minute cancellations, a fully refundable $50/person deposit is required to attend the program.

Travel related expenses including tolls, mileage, and parking will be reimbursed, with limitations. Air transportation will be arranged for you. Most meals will be provided on site. Learn more on our policies and guidelines page.

Made possible by:

Diamond Sponsor

Silver Sponsor

Friend Sponsors:
DrugCo Pharmacy
Octapharma

Visit the InhibitCon page to see a full list of sponsors

Did you know CHES is now a 501(c)3?

CHES Foundation is celebrating its first full year as a nonprofit and 15 years as a patient education/advocacy resource dedicated to serving those with inhibitors, ultra-rare factor/platelet disorders and those who menstruate.